Abstract
Eighty-nine thalassemic patients with chronic hepatitis C were treated with interferon alpha-2a for 12 months and followed up for 8 years. Interferon induced sustained virologic and biochemical response in 45% of participants and histologic improvement in 50% of patients who had paired liver biopsies. Splenectomy was the only independent predictor of an unfavorable outcome.
MeSH terms
-
Adolescent
-
Adult
-
Female
-
Follow-Up Studies
-
Hepatitis C, Chronic / blood
-
Hepatitis C, Chronic / complications*
-
Hepatitis C, Chronic / drug therapy*
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / therapeutic use*
-
Male
-
Prospective Studies
-
RNA, Viral / blood
-
Recombinant Proteins
-
beta-Thalassemia / blood
-
beta-Thalassemia / complications*
-
beta-Thalassemia / drug therapy*
Substances
-
Interferon alpha-2
-
Interferon-alpha
-
RNA, Viral
-
Recombinant Proteins